Clinical Trial Update: SNIFF - 3-Week Aptar CPS Device [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of the SNIFF 3-Week Aptar CPS device sponsored by Wake Forest University Health Sciences has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease Early-onset
• Cognitive Impairment

Drugs mentioned

• SNIFF - 3-Week Aptar CPS Device

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Mild Cognitive Impairment, Cognitive Impairment | Phase 2 | Status: WITHDRAWN